Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib + Imatinib vs Imatinib for Treatment-free Remission in CML
NCT05413915Phase 3Terminated
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of asciminib in chronic myeloid leukemia (CML) (2 arms). Primary endpoint: Event-Free Survival. Started Nov 2023; status: terminated.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05413915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413915.